RxDoctor Payments Data

Chelsea Hendrix

Family · Savannah, GANPI 1104341247

Payments from drug & device makers

$5,985in general payments, 2019–2025

Across 307 payments — averaging $19.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$692
  • Johnson & Johnson$477
  • Sanofi$244
  • Gilead$166
  • Regeneron Healthcare Solutions, Inc.$129
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$5,985100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,985 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$63,318
Medicare patients
458
Services billed
641

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab13$339,481
XifaxanRifaximin29$98,195
LinzessLinaclotide80$78,991
CreonLipase/Protease/Amylase23$52,985
ZenpepLipase/Protease/Amylase12$31,597
TrulancePlecanatide19$24,514
Dexlansoprazole DrDexlansoprazole34$7,657
Lansoprazole22$5,698
Pantoprazole Sodium362$5,339
Colesevelam Hcl64$4,366
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates60$4,095
Colestipol Hcl36$3,839
Famotidine218$2,630
Sucralfate38$1,675
Lubiprostone16$1,565

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$477$339,48113 claims
AbbVieLinzess, Creon$2,952$131,976103 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$692$122,70948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →